Abbott unveils new delivery system for electrode implantation procedure

A “next-generation” delivery system has been launched by Abbott to streamline the electrode implantation process for its Proclaim DRG neurostimulation system. Treatments for individuals with complex regional pain syndrome (CRPS) types 1 and 2 are aimed to be improved by this advancement, which is known for causing extreme pain. 

According to the company, the dorsal root ganglion (DRG) is a nerve cell cluster present along the spine that regulates pain signals from certain regions such as the hip, ankle and foot with Health outcomes. Developed by the company, the Proclaim DRG therapy claims to be the “first and only” DRG technology that gained approval for treating CRPS of the lower limbs. This system includes a small battery-operated implantable pulse generator that produces electrical stimulation and it is one of the essential innovations in Pharmaceutical industry. 

The delivery system is considered essential for accurately positioning electrodes within the anatomy of the dorsal root ganglion (DRG). Its enhanced maneuverability and robustness are designed to facilitate the implantation process for medical professionals. Abbott highlighted that the placement of the DRG requires the use of a needle to reach the epidural space, followed by the guidance of the lead to the DRG with the assistance of imaging techniques. 

Abbott neuromodulation medical director Allen Burton said: “Research shows treating CRPS with targeted DRG neurostimulation results in significantly better outcomes in terms of pain relief and functional improvements than traditional spinal cord stimulation approaches.